Greenwich LifeSciences Management
Management Kriterienprüfungen 1/4
Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.
Wichtige Informationen
Snehal Patel
Geschäftsführender
US$2.8m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 20.2% |
| Amtszeit als Geschäftsführer | 14.3yrs |
| Eigentum des Geschäftsführers | 42.9% |
| Durchschnittliche Amtszeit des Managements | keine Daten |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 14.3yrs |
Jüngste Management Updates
Recent updates
Here's Why We're Not Too Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Situation
Jan 12
We're Not Very Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Rate
Jan 29Greenwich LifeSciences: Persevering CEO And Interesting Data
Sep 06Greenwich LifeSciences halts stock buyback program
Jul 11Greenwich LifeSciences: A First Look
May 19Greenwich LifeSciences: Insider Buying And Buybacks Telegraph This Company's Vast Potential
Apr 21Companies Like Greenwich LifeSciences (NASDAQ:GLSI) Are In A Position To Invest In Growth
Feb 01We Think Greenwich LifeSciences (NASDAQ:GLSI) Can Afford To Drive Business Growth
Sep 30We're Not Very Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Rate
Apr 04Are Insiders Buying Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock?
Feb 16
What Is The Ownership Structure Like For Greenwich LifeSciences, Inc. (NASDAQ:GLSI)?
Dec 25Greenwich LifeSciences: Optimism On 'GP2' Breast Cancer Immunotherapy Candidate
Dec 23Greenwich LifeSciences under stress on pricing upsized $26.4M equity offering
Dec 18Greenwich LifeSciences inks deal with Westport Bio for pre-clinical coronavirus vaccine candidates
Dec 15Greenwich LifeSciences trebles in value as breast cancer therapy shines in mid-stage trial
Dec 09Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$9m |
| Dec 31 2023 | US$3m | US$557k | -US$9m |
| Sep 30 2023 | n/a | n/a | -US$9m |
| Jun 30 2023 | n/a | n/a | -US$9m |
| Mar 31 2023 | n/a | n/a | -US$8m |
| Dec 31 2022 | US$2m | US$506k | -US$8m |
| Sep 30 2022 | n/a | n/a | -US$7m |
| Jun 30 2022 | n/a | n/a | -US$6m |
| Mar 31 2022 | n/a | n/a | -US$6m |
| Dec 31 2021 | US$1m | US$450k | -US$5m |
| Sep 30 2021 | n/a | n/a | -US$3m |
| Jun 30 2021 | n/a | n/a | -US$3m |
| Mar 31 2021 | n/a | n/a | -US$2m |
| Dec 31 2020 | US$999k | US$115k | -US$2m |
| Sep 30 2020 | n/a | n/a | -US$1m |
| Jun 30 2020 | n/a | n/a | -US$1m |
| Mar 31 2020 | n/a | n/a | -US$4m |
| Dec 31 2019 | US$139k | n/a | -US$3m |
Vergütung im Vergleich zum Markt: SnehalDie Gesamtvergütung ($USD2.75M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD1.62M).
Entschädigung vs. Einkommen: SnehalDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.
Geschäftsführer
Snehal Patel (60 yo)
14.3yrs
Amtszeit
US$2,750,029
Vergütung
Mr. Snehal S. Patel has been Chief Executive Officer of Greenwich Lifesciences Inc. since June 2016 and has been Chief Financial Officer and Director since February 2010. He serves as Managing Director at...
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO, CFO & Director | 14.3yrs | US$2.75m | 42.9% $ 89.9m | |
| Founder & Independent Director | 17.8yrs | US$65.64k | 2.43% $ 5.1m | |
| Chief Medical Officer & Director | 4.8yrs | keine Daten | 0.70% $ 1.5m | |
| Independent Chairman of the Board | 15.3yrs | US$98.39k | 4.82% $ 10.1m | |
| Independent Director | 4.8yrs | US$65.64k | 3.08% $ 6.5m |
14.3yrs
Durchschnittliche Betriebszugehörigkeit
73yo
Durchschnittliches Alter
Erfahrener Vorstand: GLSIDie Vorstandsmitglieder sind sehr erfahren ( 14.3 ).